Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v20-EN Version v19-FR
Language English French
Date Updated 2023-05-12 2023-05-11
Drug Identification Number 02243676 02243676
Brand name RECOMBIVAX HB RECOMBIVAX HB
Common or Proper name (hepatitis B vaccine [recombinant]) (hepatitis B vaccine [recombinant])
Company Name MERCK CANADA INC MERCK CANADA INC
Ingredients HEPATITIS B SURFACE ANTIGEN HEPATITIS B SURFACE ANTIGEN
Strength(s) 10MCG 10MCG
Dosage form(s) SUSPENSION SOLUTION SUSPENSION SOLUTION
Route of administration INTRAMUSCULAR INTRAMUSCULAR INTRAMUSCULAR INTRAMUSCULAR
Packaging size 10MCG/1ML 1DOSE VIAL 10MCG/1ML 1DOSE VIAL
ATC code J07BC J07BC
ATC description VIRAL VACCINES VIRAL VACCINES
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2022-12-02 2022-12-02
Actual start date 2022-12-01 2022-12-01
Estimated end date 2023-05-12 2023-05-12
Actual end date 2023-05-11 2023-05-11
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Remaining doses are reserved for the public immunization program. Limited quantities available for private orders. Remaining doses are reserved for the public immunization program. Limited quantities available for private orders.
Health Canada comments